Class A
ISIN: LU1491986011
CATEGORY: Sector Equity Biotechnology
KEY INFORMATIONat 20.01.2022
Net Asset Value153,13 EUR
Fund Size (mln)14.453.620 EUR
Launch Date 2 ott 2012
BenchmarkBENCHMARK COMPOSITE 17389
MANAGEMENT INFORMATION
SicavPHARUS SICAV
Management CompanyPHARUS MANAGEMENT LUX SA
Investment ManagerPharus Asset Management SA
DOCUMENTS
N.A.
RISK & REWARD PROFILE
Lower Risk
Highest Risk
Potentially lower return
Potentially higher return
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
INVESTMENT OBJECTIVE
The sub-fund aims to achieve growth by investing in equities or similar securities issued by biopharmaceutical companies that are at the forefront of innovation in the medical sector. The sub-fund will invest at least two-thirds of its total assets in equities issued by companies operating in this sector.
MANAGER COMMENT
The fund recorded a negative performance of -4.20% in December and a performance during 2021 of -15.39%.
The fund invests in companies in the pharmaceutical, medical and biotechnology sectors, with a particular interest in the latest technological and scientific innovations.
Specifically, the fund focuses on small and mid-cap companies, pursuing high diversification through a portfolio of over 150 names. We remain focused on the US market, maintaining full hedging against the Euro / US Dollar exchange rate.
The reasons for this negative performance that characterized 2021 can be found in the sharp decrease in M&As compared to previous years, and in the almost total interest of investors on the development of therapies related to the treatment of the coronavirus, leading to neglect the progress achieved in the treatment of diabetes and in oncology.
In addition, the fund suffered from the evident underperformance of the Russell 2000 compared to the S&P 500.
We believe that today the fund represents an excellent investment opportunity, since the fundamentals of the companies have not worsened and today they present very interesting valuations for one of the sectors that will certainly prove to be one of the key drivers of the coming years.
For 2022, we expect a strong recovery in the biotech sector, given the performance of the past year, and the development of new therapies and diagnoses.
PERFORMANCE
Last updated on 20.01.2022
ASSET ALLOCATION
*
No coverage or derivatives are included
CURRENCY ALLOCATION
*
No coverage or derivatives are included
COUNTRY ALLOCATION
TOP TEN HOLDING
Invesco Nasdaq Biotech 2 %
Dicerna Pharmaceuticals Inc 1.5 %
Arena Pharmaceuticals Inc 1.38 %
Biohaven Pharmaceutical Hold 1.03 %
Cytokinetics Inc 0.94 %
Turning Point Therapeutics I 0.89 %
Fate Therapeutics Inc 0.89 %
Biocryst Pharmaceuticals Inc 0.88 %
Blueprint Medicines Corp 0.86 %
Incyte Corp 0.86 %
SECTOR ALLOCATION
Current risk profile selected: